25 februari 2011:bron: Medscape

Twee recente studies tonen aan dat bisfosfonaten botproblemen kunnen veroorzaken in de kaak. En dit geldt voor alle vormen van bisfosfonaten, zowel welke intraveneus worden gegeven , zoals Zometa - Zoledronic Acid en APD - Pamidronate, maar ook voor de oraal ingenomen bisfosfonaten. Medscape beschrijft uitvoerig de studie, klik daarvoor hier. En dit is een uitleg van de resultaten uit het abstract:

This larger of the 2 studies, led by Andrei Barasch, DMD, MDSc, FAAHD, from the University of Alabama School of Dentistry, Birmingham, investigated 191 ONJ cases (154 [80%] in cancer patients) and 573 matched control subjects from 119 dental practices in the United States.

This team found that bisphosphonate use was strongly associated with ONJ, with an odds ratio of 299.5 for intravenous drugs and of 12.2 for oral drugs.

They also calculated that using bisphosphonates for less than 2 years was associated with a 10-fold risk for ONJ; use for more than 2 years nearly quadrupled that risk.

"This case–control study, conducted in a broad cross-section of dental practices, confirms an elevated risk for ONJ among patients treated with bisphosphonates, with a large effect in the range suggestive of a causal link," the team concludes.

All formulations of bisphosphonates were associated with ONJ, with the exception of oral etidronate — but this drug was used by only 3 participants in the study, the researchers note.

A majority (83%) of the people with ONJ had used bisphosphonates: 48% used intravenous zolendronic acid, 23% used intravenous pamidronate, 38% used oral alendronate, 5% used oral ibandronate, and 8% used oral risedronate.

The risk of developing ONJ was higher for the more potent bisphosphonates, such as intravenous zolendronic acid and pamidronate (both indicated for use in cancer patients), but the risk was also there for weaker oral formulations, such as alendronate (which are used for osteoporosis).

This significant association between the less potent bisphosphonates and ONJ confirms previous reports, and "has significant clinical implications, since millions have been treated with these drugs," the researchers note. Read more>>>>>


Plaats een reactie ...

Reageer op "Bisphosphonaten vaak oorzaak van botproblemen in de kaak - osteonecrosis - blijkt uit 2 recente studies"


Gerelateerde artikelen